Pfizer (PFE), Spark (ONCE) Initiate Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
